Press releases
Three-year results from ECLIPSE study indicate that COPD patients may require prevention strategies to manage exacerbations, regardless of disease severity
Today the New England Journal of Medicine published results from ECLIPSE (Evaluation of COPD* Longitudinally to Identify Predictive Surrogate End-points), an extensive research programme sponsored by GlaxoSmithKline (GSK) designed to advance understanding of the underlying mechanisms of Chronic Obstructive Pulmonary Disease (COPD), a disease which accounts for 2.75 million deaths worldwide each year1, as well as define markers of disease progression
GSK and BJD collaborate on a new educational programme to reduce global burden of joint pain
The Bone and Joint Decade (BJD) international initiative and GlaxoSmithKline (GSK) today announced the launch of the LIBERATE™ joint pain management programme during the BJD’s World Conference in Lund, Sweden. The BJD, which is endorsed by the United Nation’s World Health Organisation, and GSK have partnered to develop the global programme that provides information on practical and clinically proven techniques that people can use to self-manage their joint pain.
Audio recording of meeting between GSK and Dr Nissen to discuss Avandia
Audio recording of meeting between GSK and Dr Nissen to discuss Avandia
GSK announces succession plan for Chief Financial Officer
GlaxoSmithKline plc (GSK) today announces that Julian Heslop is to retire as Chief Financial Officer and Executive Director of the company at the end of March 2011. He will be succeeded by Simon Dingemans who is appointed Chief Financial Officer designate and Executive Director effective 4 January 2011.
Galapagos reaches agreement to acquire GlaxoSmithKline research centre in Zagreb, Croatia
R&D operations in Zagreb fulfil Galapagos’ growing R&D capacity requirements
GSK signs agreement with Lonza to secure capacity and expertise in biological manufacturing to support ongoing development of GSK’s biopharmaceuticals portfolio
GlaxoSmithKline (GSK) and Lonza today announced that they have entered into a new agreement under which Lonza will support the ongoing development of GSK’s biopharmaceutical pipeline by supplying manufacturing capacity for five early stage monoclonal antibodies.
GlaxoSmithKline and Genmab announce start of ofatumumab Phase III combination study in non-Hodgkin’s lymphoma
GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today the start of a Phase III study in patients with indolent B-cell non-Hodgkin’s lymphoma (B-NHL) who did not respond to or progressed during, or within 6 months of a rituximab containing regimen. Under the terms of Genmab’s collaboration with GlaxoSmithKline (GSK), Genmab will receive a milestone payment of approximately DKK 116 million (approximately USD 20 million), triggered by the treatment of the first patient in the study
BBC Panorama – 6 September 2010: “A Risk Worth Taking?” Programme. GlaxoSmithKline Right of Reply Statement
Patient safety is our first priority. We strongly refute any allegation that our actions have put patients at risk.
GlaxoSmithKline pre-broadcast statement: BBC Panorama, 6 September 2010
GlaxoSmithKline today issued the following statement in anticipation of the BBC Panorama programme, 'A risk worth taking?' which is scheduled to be aired this evening.
GlaxoSmithKline responds to British Medical Journal article regarding Avandia® (rosiglitazone)
GlaxoSmithKline (GSK) continues to work in the best interest of diabetes patients who face this chronic and serious disease. Patients taking Avandia should speak with their doctor about their treatment and any questions they may have regarding their medicine.
